This segment focuses on the development of oral recombinant vaccines against a range of infectious diseases, including norovirus, influenza, respiratory syncytial virus (RSV), and coronavirus (SARS-CoV-2). Vaxart employs its proprietary oral vaccine platform to deliver these vaccines in tablet form, aiming to simplify administration and improve patient compliance. Research and development efforts involve preclinical studies, Phase 1 and Phase 2 clinical trials to assess safety and efficacy. The company is exploring potential cross-protection capabilities of its vaccines. The goal is to create vaccines that are more accessible, easier to distribute, and can be self-administered, particularly beneficial in resource-limited settings and for pandemic preparedness. Vaxart's approach seeks to stimulate both systemic and mucosal immunity, potentially offering broader and more durable protection against infection.

Vaxart is also engaged in the development of therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus (HPV). This segment leverages the company's oral vaccine platform to target HPV-related diseases. Research and development activities include preclinical studies and clinical trials to evaluate the safety and efficacy of these therapeutic vaccines. The focus is on developing treatments that can stimulate the immune system to clear HPV infections and prevent the progression to cervical cancer. Vaxart's oral vaccine approach offers a non-invasive alternative to traditional treatments, potentially improving patient outcomes and quality of life. The company aims to address a significant unmet medical need in the treatment of HPV-related diseases.